GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA IN COMBINATION PRODUCTS
This article was originally published in The Tan Sheet
Executive Summary
GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA IN COMBINATION PRODUCTS to FDA on Sept. 8. The submission includes five clinical studies and two guinea pig studies sponsored by Givaudan-Roure customers outside the U.S., as well as other data intended to support a Category I (safe and effective) listing of the broad- spectrum sunscreen. The data are intended to bolster the company's citizen petition seeking monograph status for Parsol 1789 (avobenzone).